Ademola S Ojo1, Somtochukwu G Ojukwu2, Joseph Asemota2, Oluwasegun Akinyemi3, Mojisola O Araoye4, Mohammed Saleh5, Ahmed Ali6, Ravi Sarma6. 1. Department of Internal Medicine, Howard University Hospital, Washington, DC, USA. aojo@huhosp.org. 2. Department of Internal Medicine, Howard University Hospital, Washington, DC, USA. 3. Clive O Callender, MD Howard-Harvard Outcome Research Center, Howard University College of Medicine, Washington, DC, USA. 4. Hematology/Oncology Division, Warren Alpert Medical School of Brown University, Providence, RI, USA. 5. Department of Internal Medicine, University of Missouri, Columbia, MO, USA. 6. Department of Medicine, Hematology/Oncology Division, Howard University Hospital, Washington, DC, USA.
Abstract
BACKGROUND: Smoldering multiple myeloma (SMM) is an intermediate pre-malignant condition with individuals having a distinct risk of progression to overt myeloma. The optimal management option has remained controversial due to the heterogeneous nature of the condition in which progression to overt diseases is variable. The question of who, when, and what to use for the treatment of SMM remains equivocal. We performed a systematic review of randomized controlled trials and summarized the current evidence supporting the best approach to the management of SMM. METHODS: A comprehensive literature search of Medline/PubMed, PubMed Central, Embase, Scopus, Web of Science, Wiley Cochrane Library, CINAHL, clinicaltrial.gov, and conference proceedings of ASCO, ASH, EHA, and ESMO was performed on October 25, 2020. Synthesis of the result was done using narrative analysis. RESULT: Of the total 1560 identified records, 10 eligible studies involving 1157 patients made up of 580 in the intervention group and 577 in the control group were included in this review. Three early trials of melphalan and prednisone fail to demonstrate any significant impact on disease progression with major toxicities reported. Three trials on bisphosphonate monotherapy show reduced skeletal-related events without any clinical effect on disease progression. Lenalidomide monotherapy or as part of a combination therapy demonstrates superiority in delaying disease progression over observation. Only Lenalidomide and dexamethasone combination demonstrated superior overall survival over observation across the trials. CONCLUSION: Trials of lenalidomide in a less intensive approach has shown promise in delaying disease progression and should be investigated further in clinical trials.
BACKGROUND: Smoldering multiple myeloma (SMM) is an intermediate pre-malignant condition with individuals having a distinct risk of progression to overt myeloma. The optimal management option has remained controversial due to the heterogeneous nature of the condition in which progression to overt diseases is variable. The question of who, when, and what to use for the treatment of SMM remains equivocal. We performed a systematic review of randomized controlled trials and summarized the current evidence supporting the best approach to the management of SMM. METHODS: A comprehensive literature search of Medline/PubMed, PubMed Central, Embase, Scopus, Web of Science, Wiley Cochrane Library, CINAHL, clinicaltrial.gov, and conference proceedings of ASCO, ASH, EHA, and ESMO was performed on October 25, 2020. Synthesis of the result was done using narrative analysis. RESULT: Of the total 1560 identified records, 10 eligible studies involving 1157 patients made up of 580 in the intervention group and 577 in the control group were included in this review. Three early trials of melphalan and prednisone fail to demonstrate any significant impact on disease progression with major toxicities reported. Three trials on bisphosphonate monotherapy show reduced skeletal-related events without any clinical effect on disease progression. Lenalidomide monotherapy or as part of a combination therapy demonstrates superiority in delaying disease progression over observation. Only Lenalidomide and dexamethasone combination demonstrated superior overall survival over observation across the trials. CONCLUSION: Trials of lenalidomide in a less intensive approach has shown promise in delaying disease progression and should be investigated further in clinical trials.
Authors: Timothy A Brighton; Amit Khot; Simon J Harrison; David Ghez; Brendan M Weiss; Andres Kirsch; Hila Magen; Mercedes Gironella; Albert Oriol; Matthew Streetly; Britte Kranenburg; Xiang Qin; Rajesh Bandekar; Peter Hu; Mary Guilfoyle; Ming Qi; Sepideh Nemat; Hartmut Goldschmidt Journal: Clin Cancer Res Date: 2019-03-19 Impact factor: 12.531
Authors: Robert B Conley; Gemma Adib; Robert A Adler; Kristina E Åkesson; Ivy M Alexander; Kelly C Amenta; Robert D Blank; William Timothy Brox; Emily E Carmody; Karen Chapman-Novakofski; Bart L Clarke; Kathleen M Cody; Cyrus Cooper; Carolyn J Crandall; Douglas R Dirschl; Thomas J Eagen; Ann L Elderkin; Masaki Fujita; Susan L Greenspan; Philippe Halbout; Marc C Hochberg; Muhammad Javaid; Kyle J Jeray; Ann E Kearns; Toby King; Thomas F Koinis; Jennifer Scott Koontz; Martin Kužma; Carleen Lindsey; Mattias Lorentzon; George P Lyritis; Laura Boehnke Michaud; Armando Miciano; Suzanne N Morin; Nadia Mujahid; Nicola Napoli; Thomas P Olenginski; J Edward Puzas; Stavroula Rizou; Clifford J Rosen; Kenneth Saag; Elizabeth Thompson; Laura L Tosi; Howard Tracer; Sundeep Khosla; Douglas P Kiel Journal: J Bone Miner Res Date: 2019-12-01 Impact factor: 6.741
Authors: Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon Journal: Haematologica Date: 2015-03-13 Impact factor: 9.941
Authors: Angela Dispenzieri; Robert A Kyle; Jerry A Katzmann; Terry M Therneau; Dirk Larson; Joanne Benson; Raynell J Clark; L Joseph Melton; Morie A Gertz; Shaji K Kumar; Rafael Fonseca; Diane F Jelinek; S Vincent Rajkumar Journal: Blood Date: 2007-10-17 Impact factor: 22.113